Povorcitinib not checked

Incyte Corporation · INCB054707 · INCB54707

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
8 active
24 in total · 10 in the EU
Targets
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
Tested for
Hidradenitis Suppurativa (HS) (3 trials), NonSegmental Vitiligo (2 trials), Prurigo Nodularis (2 trials), Moderate to Severe Asthma
Main trialPhase 3
“This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.”In the company’s words, NCT06113445 on ClinicalTrials.gov
Other names
INCB054707 · INCB54707

Other drugs for Hidradenitis Suppurativa (HS)

All 29 drugs for Hidradenitis Suppurativa (HS)

Coming up4

Changes2

Last 90 days

Trials24

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 24 Feb 2026 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Phase 3Active, not recruiting 17 Mar 2026 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Phase 3Active, not recruiting 28 Sep 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Phase 3Active, not recruiting 19 Oct 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Phase 3Active, not recruiting 26 Dec 2026 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3Recruiting 28 Feb 2028 Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Phase 2Active, not recruiting 20 Nov 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Phase 2Recruiting 25 Mar 2028 Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3Completed 7 Jan 2025 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 3Completed 3 Feb 2025 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 2Completed 22 Apr 2019 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Phase 2Completed 13 Aug 2019 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Phase 2Completed 15 Dec 2021 To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Phase 2Completed 24 May 2022 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
Phase 2Completed 11 Aug 2023 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Phase 2Completed 28 Feb 2025 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Phase 1Completed 25 Jan 2022 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
Phase 1Completed 30 Jun 2023 A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Phase 1Completed 7 Feb 2024 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
Phase 1Completed 7 Jun 2024 A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
Phase 1Completed 10 Sep 2024 A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
Phase 1Completed 18 Sep 2024 A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
Phase 1Completed 15 Jan 2025 A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
Phase 1Completed 8 Sep 2026 A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Povorcitinib

Following is part of Solo: you see every change to Povorcitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in